2008
DOI: 10.1016/j.ijantimicag.2007.07.032
|View full text |Cite
|
Sign up to set email alerts
|

Impact of Toll-like receptor signalling on urinary tract infection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
20
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 25 publications
(22 citation statements)
references
References 31 publications
(48 reference statements)
1
20
0
1
Order By: Relevance
“…Epithelial cells are the first line of host defense against invading pathogens [9]. In addition, epithelial cells contribute to the initiation of host innate and adaptive immune responses by producing chemokines, cytokines, and antimicrobial peptides [23]. The immune response to UPEC is initiated by bacterial invasion of bladder epithelial cells, which induces the production of proinflammatory cytokines such as IL-6 and IL-8 and recruits neutrophils to the infection Fig.…”
Section: Discussionmentioning
confidence: 99%
“…Epithelial cells are the first line of host defense against invading pathogens [9]. In addition, epithelial cells contribute to the initiation of host innate and adaptive immune responses by producing chemokines, cytokines, and antimicrobial peptides [23]. The immune response to UPEC is initiated by bacterial invasion of bladder epithelial cells, which induces the production of proinflammatory cytokines such as IL-6 and IL-8 and recruits neutrophils to the infection Fig.…”
Section: Discussionmentioning
confidence: 99%
“…Pharmacological agents (TLR agonists) contain synthetic lipopeptide derivatives from bacterial lipoproteins, ssRNA, CpG motifcontaining oligonucleotides or CpG oligodeoxynucleotides. Patients who are susceptible to UTI, in which defective TLR mutants might be responsible for increased infection rates, could be treated with specific TLR-modulating drugs to conquer impaired immune defense systems, particularly in chronic recurrent UTI [40].…”
Section: Tlr-based Drug Developmentmentioning
confidence: 99%
“…Stimulation of TLR-related antimicrobial signaling of target cells (monocytes, DCs, lymphocytes) via immunoadjuvants may reflect an innovative form of immunization, similar to-or even more effective than-the conventional vaccination that targets the pathogen [41]. In a similar method, recent pre-clinical studies used TLR ligands to treat viral diseases and to improve antitumor treatment (e.g., ligands that play as agonists for TLR7 activation against cancer cells) [40].…”
Section: Tlr Agonistsmentioning
confidence: 99%
See 1 more Smart Citation
“…When TLR4 and TLR5 are bound by ligand they are phosphorylated on the cytoplasmic domain. Activation of the TLRs initiates signaling of immune and inflammation responses [22][23][24][25][26]. TLR4 activation by LPS or P fimbriae binding results in secretion of IL-6 and IL-8.…”
Section: Toll-like Receptorsmentioning
confidence: 99%